All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Glucagon-like peptide-1 receptor agonists and muscle mass effects

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F25%3A00085818" target="_blank" >RIV/00023001:_____/25:00085818 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11310/25:10515663

  • Result on the web

    <a href="https://www.sciencedirect.com/science/article/pii/S1043661825003524?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1043661825003524?via%3Dihub</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.phrs.2025.107927" target="_blank" >10.1016/j.phrs.2025.107927</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Glucagon-like peptide-1 receptor agonists and muscle mass effects

  • Original language description

    Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of obesity, demonstrating significant efficacy in inducing weight loss and improving metabolic parameters. However, emerging clinical and paraclinical evidence suggests that these agents may also contribute to an unintended reduction in skeletal muscle mass, potentially exacerbating or precipitating sarcopenic obesity, particularly in older or frail individuals with limited muscular reserves. This review critically examines current data on the effects of GLP-1 RAs on body composition, explores the underlying pathophysiological mechanisms of skeletal muscle wasting, and offers evidence-based strategies for attenuating these potential adverse outcomes. While GLP-1 RAs therapy remains central to obesity management, optimizing its use through early recognition and management of associated risks is essential to preserve muscular health, patient functional status and quality of life.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30104 - Pharmacology and pharmacy

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2025

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Pharmacological research

  • ISSN

    1043-6618

  • e-ISSN

    1096-1186

  • Volume of the periodical

    220

  • Issue of the periodical within the volume

    October 2025

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    19

  • Pages from-to

    "art. no. 107927"

  • UT code for WoS article

    001561951000001

  • EID of the result in the Scopus database

    2-s2.0-105014122899